Merck Gains Phase II SARM For Muscle Loss With GTx Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck, GTx pool their selective androgen receptor modulator programs in a deal valued at over $500 million.
You may also be interested in...
GTx/Merck SARM Demonstrates Muscle Improvements In Cancer Patients
Phase II trial evaluating Ostarine in patients with cancer-induced muscle loss meets its primary endpoint.
GTx/Merck SARM Demonstrates Muscle Improvements In Cancer Patients
Phase II trial evaluating Ostarine in patients with cancer-induced muscle loss meets its primary endpoint.
GTx Closer To Filing NDA For Acapodene With Promising Phase III Results
Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.